The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Incidence of adverse event and adverse drug reaction. [ Time Frame: Once a week up to 5years ]
Secondary Outcome Measures :
Change of vital sign, physical and clinical examination, anti-idurasulfase-beta antibody status. [ Time Frame: Base line and every three months up to 5years.(exception: clinical examination-> baseline and every six months up to 5years) ]
Other Outcome Measures:
Percent change of urine GAG. [ Time Frame: Baseline and every three months up to 5years. ]
Percent change of 6 minute walking test. [ Time Frame: Baseline and every 6 months up to 5years. ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.